Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
Completed · Phase 3
Conditions studied: Gastroesophageal Reflux Disease (GERD)
In brief
The purpose of this study is to determine the safety and efficacy of Rabeprazole extended release (ER) 50 mg versus Esomeprazole 40 mg for healing and symptomatic relief among subjects with erosive gastroesophageal reflux disease (GERD).
Key facts
- Study ID
- NCT00658528
- Run by
- Eisai Inc.
- People needed
- 1061
- Starts
- 2008-02-01
- Expected to finish
- 2010-01-01
- Last updated by the study team
- 2015-12-21
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Study site — Isidro Casanova, La Matanza, BUE, Argentina
- Study site — Ramos Mejía, BUE, Argentina
- Study site — San Isidro, BUE, Argentina
- Study site — Capital Federal, CBA, Argentina
- Study site — Mendoza, MEN, Argentina
- Study site — Rosario, SFE, Argentina
- Study site — Rosario, SFE, Argentina
- Study site — Rosario, SFE, Argentina
- Study site — San Juan, SJN, Argentina
- Study site — Five Dock, New South Wales, Australia
- Study site — Carina Heights, Queensland, Australia
- Study site — Kippa-Ring, Queensland, Australia
- Study site — Box Hill, Victoria, Australia
- Study site — Frankston, Victoria, Australia
- Study site — Malvern, Victoria, Australia
- Study site — Plovdiv, Bulgaria, Bulgaria
- Study site — Sofia, Bulgaria, Bulgaria
- Study site — Sofia, Bulgaria, Bulgaria
- Study site — Sofia, Bulgaria, Bulgaria
- Study site — Sofia, Bulgaria, Bulgaria
- Study site — Stara Zagora, Bulgaria, Bulgaria
- Study site — Varna, Bulgaria, Bulgaria
- Study site — Saint John, New Brunswick, Canada
- Study site — St. John's, Newfoundland and Labrador, Canada
- Study site — Anaheim, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.